149 related articles for article (PubMed ID: 37097451)
1. Characterization of hepatobiliary phase hypointense nodules without arterial phase hyperenhancement on gadoxetic acid-enhanced MRI via contrast-enhanced ultrasound using perfluorobutane.
Bae JS; Lee JY; Suh KS; Hong SK; Yoon JH; Kim YJ; Yu SJ; Lee JH; Cho EJ; Lee YB; Han JK
Abdom Radiol (NY); 2023 Jul; 48(7):2321-2330. PubMed ID: 37097451
[TBL] [Abstract][Full Text] [Related]
2. Radiologic-Pathologic Correlation of Hepatobiliary Phase Hypointense Nodules without Arterial Phase Hyperenhancement at Gadoxetic Acid-enhanced MRI: A Multicenter Study.
Joo I; Kim SY; Kang TW; Kim YK; Park BJ; Lee YJ; Choi JI; Lee CH; Park HS; Lee K; Kim H; Yu E; Kang HJ; Ha SY; Kim JY; Ahn S; Jung ES; Kim BH; Han HS; Lee JM
Radiology; 2020 Aug; 296(2):335-345. PubMed ID: 32484414
[TBL] [Abstract][Full Text] [Related]
3. Hypervascular transformation of hepatobiliary phase hypointense nodules without arterial phase hyperenhancement on gadoxetic acid-enhanced MRI: long-term follow-up in a surveillance cohort.
Park HJ; Lee TY; Kim SY; Kim MJ; Singal AG; Lee SJ; Won HJ; Byun JH; Lim YS
Eur Radiol; 2022 Aug; 32(8):5064-5074. PubMed ID: 35229195
[TBL] [Abstract][Full Text] [Related]
4. Hepatobiliary phase hypointense nodule without arterial phase hyperenhancement: are they at risk of HCC recurrence after ablation or surgery? A systematic review and meta-analysis.
Kim TH; Woo S; Han S; Suh CH; Lee DH; Lee JM
Eur Radiol; 2020 Mar; 30(3):1624-1633. PubMed ID: 31776747
[TBL] [Abstract][Full Text] [Related]
5. Risk Factors for Hypervascularization in Hepatobiliary Phase Hypointense Nodules without Arterial Phase Hyperenhancement: A Systematic Review and Meta-analysis.
Kim TH; Woo S; Han S; Suh CH; Do RKG; Lee JM
Acad Radiol; 2022 Feb; 29(2):198-210. PubMed ID: 32962925
[TBL] [Abstract][Full Text] [Related]
6. Contrast-enhanced US with Sulfur Hexafluoride and Perfluorobutane for the Diagnosis of Hepatocellular Carcinoma in Individuals with High Risk.
Kang HJ; Lee JM; Yoon JH; Lee K; Kim H; Han JK
Radiology; 2020 Oct; 297(1):108-116. PubMed ID: 32749211
[TBL] [Abstract][Full Text] [Related]
7. Hyperintense nodule-in-nodule on hepatobiliary phase arising within hypovascular hypointense nodule: Outcome and rate of hypervascular transformation.
Cannella R; Calandra A; Cabibbo G; Midiri M; Tang A; Brancatelli G
Eur J Radiol; 2019 Nov; 120():108689. PubMed ID: 31563835
[TBL] [Abstract][Full Text] [Related]
8. Perfluorobutane-enhanced ultrasonography with a Kupffer phase: improved diagnostic sensitivity for hepatocellular carcinoma.
Hwang JA; Jeong WK; Kang HJ; Lee ES; Park HJ; Lee JM
Eur Radiol; 2022 Dec; 32(12):8507-8517. PubMed ID: 35705829
[TBL] [Abstract][Full Text] [Related]
9. Washout appearance of hepatocellular carcinomas using standardized contrast-enhanced ultrasound (CEUS) including an extended late phase observation - Real-world data from the prospective multicentre DEGUM study.
Meitner-Schellhaas B; Jesper D; Goertz RS; Zundler S; Strobel D
Clin Hemorheol Microcirc; 2023; 84(4):413-424. PubMed ID: 37334585
[TBL] [Abstract][Full Text] [Related]
10. Imaging features of subcentimeter hypointense nodules on gadoxetic acid-enhanced hepatobiliary phase MR imaging that progress to hypervascular hepatocellular carcinoma in patients with chronic liver disease.
Jang KM; Kim SH; Kim YK; Choi D
Acta Radiol; 2015 May; 56(5):526-35. PubMed ID: 24838304
[TBL] [Abstract][Full Text] [Related]
11. Role of Contrast-Enhanced Ultrasound as a Second-Line Diagnostic Modality in Noninvasive Diagnostic Algorithms for Hepatocellular Carcinoma.
Kang HJ; Lee JM; Yoon JH; Han JK
Korean J Radiol; 2021 Mar; 22(3):354-365. PubMed ID: 33236540
[TBL] [Abstract][Full Text] [Related]
12. Comparison of extracellular and hepatobiliary MR contrast agents for the diagnosis of small HCCs.
Paisant A; Vilgrain V; Riou J; Oberti F; Sutter O; Laurent V; Rodes A; Guiu B; Cassinotto C; Trillaud H; Bricault I; Michalak S; Bruno O; Ronot M; Aubé C
J Hepatol; 2020 May; 72(5):937-945. PubMed ID: 31870951
[TBL] [Abstract][Full Text] [Related]
13. Contrast-Enhanced Ultrasound Using Perfluorobutane: Impact of Proposed Modified LI-RADS Criteria on Hepatocellular Carcinoma Detection.
Li L; Zheng W; Wang J; Han J; Guo Z; Hu Y; Li X; Zhou J
AJR Am J Roentgenol; 2022 Sep; 219(3):434-443. PubMed ID: 35441534
[No Abstract] [Full Text] [Related]
14. Retrospective validation of a new diagnostic criterion for hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout with the aid of ancillary features?
Joo I; Lee JM; Lee DH; Jeon JH; Han JK
Eur Radiol; 2019 Apr; 29(4):1724-1732. PubMed ID: 30255250
[TBL] [Abstract][Full Text] [Related]
15. Hepatobiliary phase hypointense nodule without arterial phase hyperenhancement as a risk factor for late recurrence (>1 year) of hepatocellular carcinoma after surgery.
Matsuda M; Ichikawa S; Matsuda M; Amemiya H; Ichikawa D; Onishi H; Motosugi U
Clin Radiol; 2019 Dec; 74(12):975.e1-975.e9. PubMed ID: 31540704
[TBL] [Abstract][Full Text] [Related]
16. HCCs lacking arterial phase hyperenhancement (APHE) on contrast-enhanced ultrasound (CEUS) - a diagnostic challenge. Findings from the prospective multicenter DEGUM CEUS HCC trial.
Strobel D; Agaimy A; Jesper D; Zundler S; Schellhaas B
Ultraschall Med; 2023 Dec; 44(6):606-613. PubMed ID: 36781161
[TBL] [Abstract][Full Text] [Related]
17. Contrast-enhanced US with Sulfur Hexafluoride and Perfluorobutane: LI-RADS for Diagnosing Hepatocellular Carcinoma.
Li L; Zou X; Zheng W; Li Y; Xu X; Li K; Su Z; Han J; Li Q; Zuo Y; Xie S; Wen H; Wang J; Guo Z; Zou R; Zhou J
Radiology; 2023 Aug; 308(2):e230150. PubMed ID: 37642573
[TBL] [Abstract][Full Text] [Related]
18. An improved diagnostic algorithm for subcentimeter hepatocellular carcinoma on gadoxetic acid-enhanced MRI.
Huang P; Zhou C; Wu F; Xiao Y; Qian X; Wang Y; Yang C; Zeng M
Eur Radiol; 2023 Apr; 33(4):2735-2745. PubMed ID: 36472696
[TBL] [Abstract][Full Text] [Related]
19. Doughnut-like hyperintense nodules on hepatobiliary phase without arterial-phase hyperenhancement in cirrhotic liver: imaging and clinicopathological features.
Kozaka K; Kobayashi S; Yoneda N; Kitao A; Yoshida K; Inoue D; Ogi T; Koda W; Sato Y; Gabata T; Matsui O
Eur Radiol; 2019 Dec; 29(12):6489-6498. PubMed ID: 31278576
[TBL] [Abstract][Full Text] [Related]
20. Contrast-Enhanced Ultrasound With Perfluorobutane for Hepatocellular Carcinoma Diagnosis: Comparison of Imaging Phases and Diagnostic Criteria.
Kang HJ; Lee JM; Yoon JH; Yoo J; Kim JH; Park J
AJR Am J Roentgenol; 2024 Feb; 222(2):e2330156. PubMed ID: 37991335
[No Abstract] [Full Text] [Related]
[Next] [New Search]
